b With the implementation of Amendment 3, patients were transitioned from 400-mg to 267-mg capsules, and the dose was adjusted to be as close as possible to the previous dose without exceeding the maximum permitted dose. Patients whose maintenance dose was > 2403 mg/day (≤ 3600 mg/day) continued to receive that dose. 2) 8 (9.6) Hypertension 6 (11.5) 2 (6.5) 8 (9.6) Nasal congestion 5 (9.6) 3 (9.7) 8 (9.6) Nasopharyngitis 5 (9.6) 3 (9.7) 8 (9.6) Abdominal discomfort 6 (11.5) 1 (3.2 7 (8.4) Dyspepsia 5 (9.6) 2 (6.5) 7 (8.4) Pyrexia 5 (9.6) 2 (6.5) 7 (8.4) Anemia 3 (5.8) 3 (9.7) 6 (7.2) Contusion 6 (11.5) 0 6 (7.2) Myalgia 5 (9.6) 1 (3.2) 6 (7.2) Photosensitivity reaction 1 (1.9) 5 (16.1) 6 (7.2) Respiratory failure 5 (9.6) 1 (3.2) 6 (7.2) Respiratory tract infection 4 (7.7) 2 (6.5) 6 (7.2) Skin laceration 5 (9.6) 1 (3.2) 6 (7.2) Coronary artery disease 3 (5.8) 2 (6.5) 5 (6.0) Proteinuria 4 (7.7) 1 (3.2) 5 (6.0) Pruritus 1 (1.9) 4 (12.9) 5 (6.0) Stomach discomfort 4 (7.7) 1 (3.2) 5 (6.0) IPF, idiopathic pulmonary fibrosis; TEAE, treatment-emergent adverse event. a Patients were categorized by maximum daily dose received at any time (≥ 1 prescribed dose > 2403 mg/day or all doses ≤ 2403 mg/day).
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